WB, IP
H
Endogenous
34
Rabbit IgG
#Q8N6M0
51633
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala101 of human OTUD6B protein.
Background
Protein ubiquitination and deubiquitination are reversible processes catalyzed by ubiquitinating enzymes (UBEs) and deubiquitinating enzymes (DUBs) (1,2). DUBs are categorized into 5 subfamilies: USP, UCH, OTU, MJD, and JAMM (1,2). The OTU subfamily comprises a group of approximately 100 putative cysteine proteases that are homologous to the ovarian tumor gene product of Drosophila (3). OTU domain-containing protein 6B (OTUD6B) is a member of the OTU family that has active deubiquitinase activity and plays a role in various biological processes (4,5). OTUD6B has been shown to regulate protein synthesis operating downstream of mTORC1 through its two major splicing isoforms, OTUD6B-1 and OTUD6B-2, which target different substrates (6). The switch from OTUD6B-1 to OTUD6B-2 expression may promote protein synthesis and cell proliferation in non-small cell lung cancer (NSCLC) cells (6). OTUD6B is generally upregulated in other types of cancer and is associated with poor prognosis, suggesting that it behaves as an oncogene (7). Alternatively, OTUD6B has been reported to act as a tumor suppressor in hepatocellular carcinoma (HCC) via deubiquitination of VHL and repression of HIF-1α (8). OTUD6B positively regulates type I interferon (IFN) immune response by deubiquitinating and stabilizing the transcription factor IRF3 at Lys315, and overexpression of OTUD6B in mice enhances IFN response following viral infection (9). Additionally, biallelic loss-of-function mutations in the OTUD6B gene have been shown to cause an intellectual disability syndrome that is characterized by cognitive dysfunction and seizures (10).
- Nijman, S.M. et al. (2005) Cell 123, 773-86.
- Nalepa, G. et al. (2006) Nat Rev Drug Discov 5, 596-613.
- Mevissen, T.E. et al. (2013) Cell 154, 169-84.
- Catic, A. et al. (2007) PLoS One 2, e679.
- Xu, Z. et al. (2011) PLoS One 6, e14514.
- Sobol, A. et al. (2017) Mol Cancer Res 15, 117-127.
- Zhao, G. et al. (2022) Front Immunol 13, 955091.
- Liu, X. et al. (2020) Adv Sci (Weinh) 7, 1902040.
- Wang, J. et al. (2023) mBio 14, e0033223.
- Santiago-Sim, T. et al. (2017) Am J Hum Genet 100, 676-688.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
